Concepedia

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Joseph Gligorov, Dinesh Doval, José Bines, Emilio Alba, Paulo Cortes, Jean‐Yves Pierga, Vineet Govinda Gupta, Romulo de Paula Costa, Stefanie Srock, Sabine de Ducla,

The Lancet Oncology · 2014 · 126 citations · 22 references

DOI

Concepts

References

22

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Kathy D. Miller, Molin Wang, Julie R. Gralow et al. · New England Journal of Medicine · 2007 · 3K citations · Full text

A note on quantifying follow-up in studies of failure time

M. Schemper, Terry L. Smith · Controlled Clinical Trials · 1996 · 2.5K citations

, , +9

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian et al. · Journal of the National Comprehensive Cancer Network · 2018 · 1.6K citations · Full text

, , +15

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012 · 1.2K citations · Full text

, , +7

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · Journal of Clinical Oncology · 2011 · 1.1K citations